title: Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial.
abstract: BACKGROUND
  The possible effect of inflammatory factors on decreasing BDNF has been proposed in the literature. There is conflicting evidence regarding association between BDNF level alteration and treatment response in depressive patients undergoing electroconvulsive therapy (ECT). This study investigated the effects of celecoxib in manic patients undergoing ECT on treatment response and BDNF levels.
  
  
  METHODS
  This randomized, double-blind, clinical trial included 35 manic patients who received either celecoxib (200 mg twice daily) or placebo, from one day before the 1(st) ECT session throughout the 6(th) session. BDNF levels were measured at baseline, 1(st), 3(rd) and 6(th) ECT sessions. Young mania rating scale was used to assess treatment response.
  
  
  RESULTS
  Adding celecoxib was not associated with a significant rise in BDNF levels following ECT. No difference was noted between groups in terms of treatment response. No significant association was found between changes in BDNF levels and patients' responses.
  
  
  CONCLUSIONS
  Adjuvant celecoxib did not significantly affect the BDNF level or the treatment response following ECT in manic patients.
authors.affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
authors.forename: M
authors.initials: M
authors.lastname: Kargar
authors.affiliation: Amiralam Hospital, Department of Anesthesiology, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
authors.forename: A
authors.initials: A
authors.lastname: Yoosefi
authors.affiliation: Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences,Tehran, Iran, Islamic Republic of.
authors.forename: S
authors.initials: S
authors.lastname: Akhondzadeh
authors.affiliation: Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
authors.forename: V
authors.initials: V
authors.lastname: Artonian
authors.affiliation: School of public health, Department of epidemiology and biostatistics, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
authors.forename: A
authors.initials: A
authors.lastname: Ashouri
authors.affiliation: Faculty of Pharmacy & Psychiatry and Psychology Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
authors.forename: P
authors.initials: P
authors.lastname: Ghaeli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000097:blood* / Q000188:drug therapy / Q000628:therapy*; D019208:Brain-Derived Neurotrophic Factor / Q000097:blood*; D000068579:Celecoxib / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D000068579:Celecoxib